269 related articles for article (PubMed ID: 22455451)
1. Dual function of RGD-modified VEGI-192 for breast cancer treatment.
Wu J; Jiang Y; Yang W; He Z; Meng S; Zhang Q; Lin M; Zhang H; Li W; Yang Y; Jia Y; Qian L; Lu D; Cai W; Luo G; Wang Y; Zhu X; Li M
Bioconjug Chem; 2012 Apr; 23(4):796-804. PubMed ID: 22455451
[TBL] [Abstract][Full Text] [Related]
2. Tumour-associated macrophages as a novel target of VEGI-251 in cancer therapy.
Dong X; Huang X; Yao Z; Wu Y; Chen D; Tan C; Lin J; Zhang D; Hu Y; Wu J; Wei G; Zhu X
J Cell Mol Med; 2020 Jul; 24(14):7884-7895. PubMed ID: 32452100
[TBL] [Abstract][Full Text] [Related]
3. A novel secreted splice variant of vascular endothelial cell growth inhibitor.
Chew LJ; Pan H; Yu J; Tian S; Huang WQ; Zhang JY; Pang S; Li LY
FASEB J; 2002 May; 16(7):742-4. PubMed ID: 11923219
[TBL] [Abstract][Full Text] [Related]
4. In vivo NIRF imaging-guided delivery of a novel NGR-VEGI fusion protein for targeting tumor vasculature.
Ma W; Li G; Wang J; Yang W; Zhang Y; Conti PS; Chen K
Amino Acids; 2014 Dec; 46(12):2721-32. PubMed ID: 25182731
[TBL] [Abstract][Full Text] [Related]
5. VEGI-armed oncolytic adenovirus inhibits tumor neovascularization and directly induces mitochondria-mediated cancer cell apoptosis.
Xiao T; Fan JK; Huang HL; Gu JF; Li LY; Liu XY
Cell Res; 2010 Mar; 20(3):367-78. PubMed ID: 19918267
[TBL] [Abstract][Full Text] [Related]
6. The anti-angiogenic effect and novel mechanisms of action of Combretastatin A-4.
Su M; Huang J; Liu S; Xiao Y; Qin X; Liu J; Pi C; Luo T; Li J; Chen X; Luo Z
Sci Rep; 2016 Jun; 6():28139. PubMed ID: 27338725
[TBL] [Abstract][Full Text] [Related]
7. Ursolic acid inhibits colorectal cancer angiogenesis through suppression of multiple signaling pathways.
Lin J; Chen Y; Wei L; Hong Z; Sferra TJ; Peng J
Int J Oncol; 2013 Nov; 43(5):1666-74. PubMed ID: 24042330
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth inhibitor affects the invasion, apoptosis and vascularisation in breast cancer cell line MDA-MB-231.
Gao Y; Ge Z; Zhang Z; Bai Z; Ma X; Wang Y
Chin Med J (Engl); 2014; 127(10):1947-53. PubMed ID: 24824261
[TBL] [Abstract][Full Text] [Related]
10. Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells.
Wang L; Wang Y; Du H; Jiang Y; Tang Z; Liu H; Xiang H; Xiao H
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1247-57. PubMed ID: 26464351
[TBL] [Abstract][Full Text] [Related]
11. IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
Yu DH; Liu YR; Luan X; Liu HJ; Gao YG; Wu H; Fang C; Chen HZ
Bioconjug Chem; 2015 Aug; 26(8):1702-12. PubMed ID: 26076081
[TBL] [Abstract][Full Text] [Related]
12. Advancement in the research on vascular endothelial growth inhibitor (VEGI).
Duan L; Yang G; Zhang R; Feng L; Xu C
Target Oncol; 2012 Mar; 7(1):87-90. PubMed ID: 22388993
[TBL] [Abstract][Full Text] [Related]
13. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
Chen MC; Lee CF; Huang WH; Chou TC
Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
[TBL] [Abstract][Full Text] [Related]
14. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
15. The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor.
Friedli A; Fischer E; Novak-Hofer I; Cohrs S; Ballmer-Hofer K; Schubiger PA; Schibli R; Grünberg J
Int J Biochem Cell Biol; 2009 Jul; 41(7):1572-80. PubMed ID: 19401151
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily.
Zhai Y; Yu J; Iruela-Arispe L; Huang WQ; Wang Z; Hayes AJ; Lu J; Jiang G; Rojas L; Lippman ME; Ni J; Yu GL; Li LY
Int J Cancer; 1999 Jul; 82(1):131-6. PubMed ID: 10360832
[TBL] [Abstract][Full Text] [Related]
17. VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth.
Hou W; Medynski D; Wu S; Lin X; Li LY
Clin Cancer Res; 2005 Aug; 11(15):5595-602. PubMed ID: 16061878
[TBL] [Abstract][Full Text] [Related]
18. Suppression of growth and cancer-induced angiogenesis of aggressive human breast cancer cells (MDA-MB-231) on the chorioallantoic membrane of developing chicken embryos by E-peptide of pro-IGF-I.
Chen MJ; Chiou PP; Lin P; Lin CM; Siri S; Peck K; Chen TT
J Cell Biochem; 2007 Aug; 101(5):1316-27. PubMed ID: 17286280
[TBL] [Abstract][Full Text] [Related]
19. RL66 a second-generation curcumin analog has potent in vivo and in vitro anticancer activity in ER‑negative breast cancer models.
Yadav B; Taurin S; Larsen L; Rosengren RJ
Int J Oncol; 2012 Nov; 41(5):1723-32. PubMed ID: 22971638
[TBL] [Abstract][Full Text] [Related]
20. VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo.
Zhai Y; Ni J; Jiang GW; Lu J; Xing L; Lincoln C; Carter KC; Janat F; Kozak D; Xu S; Rojas L; Aggarwal BB; Ruben S; Li LY; Gentz R; Yu GL
FASEB J; 1999 Jan; 13(1):181-9. PubMed ID: 9872942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
